Centiva Capital’s GSK GSK Stock Holding History

Centiva Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,471	Closed	-$210K	–	1398
2025 Q2	$210K	Buy	+5,471	New	+$209K	﹤0.01%	1320
2024 Q4	–	Sell	-14,488	Closed	-$592K	–	1956
2024 Q3	$592K	Sell	14,488 -9,008	-38%	-$369K	0.01%	1133
2024 Q2	$905K	Buy	+23,496	New	+$988K	0.02%	833
2022 Q1	–	Sell	-25,034	Closed	-$1.38M	–	1701
2021 Q4	$1.38M	Buy	+25,034	New	+$1.3M	0.03%	477

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Centiva Capital's GSK Position: Q3 2025 in Review

Centiva Capital sold out of GSK (GSK) in Q3 2025, closing a stake of 5,471 shares — an estimated $210K sold.

Centiva Capital first reported a position in GSK in Q4 2021 and held it in 4 quarters. The position peaked at $1.38M in Q4 2021. 896 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

Centiva Capital reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
Centiva Capital sold 5,471 GSK shares in Q3 2025, an estimated $210K.
Centiva Capital first reported a position in GSK in Q4 2021 and held it in 4 quarters.
Centiva Capital's GSK position peaked at $1.38M in Q4 2021.
896 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.